Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evommune, Inc. Common Stock (NY:EVMN)

19.73 -0.96 (-4.66%)
Streaming Delayed Price Updated: 2:58 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Evommune, Inc. Common Stock

News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade ↗
Evommune has two autoimmune disorder treatments with blockbuster potential. 
Via The Motley Fool
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? ↗
Via Stocktwits
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
Via MarketBeat
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.